Brad K. Mathis

CEO & BOARD MEMBER

Brad Mathis joins Renovo Concepts Inc. as CEO and member of the Board of Directors in 2024 as a distinguished biotech executive with over 30 years of expertise in the biotech and healthcare sectors. With a proven track record in start-up environments, Brad excels in developing companies and advancing assets toward successful commercialization. His career includes pivotal leadership roles at renowned biotech organizations such as Biogen, Alexion, Orchard Therapeutics, and Argenx.

Since 2007, Brad has been dedicated to transforming the lives of patients with severe and life-threatening conditions through the development and commercialization of Ultra-Orphan clinical solutions, significantly enhancing outcomes and saving lives. Most recently, he served as Chief Commercial Officer at Entropy Bio, an early-stage company focused on oncology. There, he led efforts to develop innovative combination treatments aimed at overcoming resistance to chemotherapy.

Brad holds a degree in Economics from Texas Tech University and brings a wealth of experience and strategic vision to his role at Renovo Concepts Inc.